FDA Launches Informal Initiative to Explore Biosimulation in the Regulatory Process | GenomeWeb

An informal effort is underway within the US Food and Drug Administration to study the potential applications of in silico modeling in the drug approval process, an agency official told BioInform last week.

Donald Stanski, scientific advisor to the director of FDA’s Center for Drug Evaluation and Research, said he is leading an emerging effort to “look critically at the degree to which in silico information can be useful in terms of both industry and agency decision making.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.